Pharmacokinetics of Dextromethorphan After Single or Multiple Dosing in Combination With Quinidine in Extensive and Poor Metabolizers
The DOI matches its Crossref record.
Abstract
Dextromethorphan (DM) pharmacological properties predict that the widely used cough suppressant could be used to treat several neuronal disorders, but it is rapidly metabolized after oral dosing. To find out whether quinidine (Q), a CYP2D6 inhibitor, could elevate and prolong DM plasma profiles, 2 multiple‐dose studies identified the lowest oral dose of Q that could be used in a fixed combination with 3 doses of DM. A multiple‐dose study in healthy subjects with an extensive or a poor enzyme metabolizer phenotype evaluated the safety and pharmacokinetic profile of a selected fixed‐dose combination (AVP‐923). Study 1 randomized 46 healthy subjects, who were extensive CYP2D6 metabolizers, to receive 0, 2.5, 10, 25, 50, or 75 mg Q twice daily in combination with 30 mg DM for 7 days. Plasma and urine samples were collected after the first and last doses for the assay of DM, dextrorphan (DX), and Q. Study 2 randomized 65 healthy extensive CYP2D6 metabolizers to 8 groups given twice‐daily 45‐ or 60‐mg DM doses combined with 0, 30, 45, or 60 mg Q for 7 days. The effects of increasing Q were not different with doses greater than 25 mg, whereas lower doses showed a dose‐related increase in plasma DM concentrations. Urinary ratios of DM/DX showed a Q dose‐ and time‐related increase in the number of subjects converted to the poor metabolizer phenotype that reached 100% on day 3 of dosing with 25 mg Q. Results from both studies indicated that 25 to 30 mg Q is adequate to maximally suppress O‐demethylation of DM. Study 3 evaluated 7 extensive metabolizers and 2 poor metabolizers given an oral capsule every 12 hours containing 30 mg Q combined with 30 mg DM. DM plasma AUC values increased in both groups of subjects during the 8‐day study. The mean urinary metabolic ratio (DM/DX) increased at least 27‐fold in extensive metabolizers by day 8. There was no effect of Q on urinary metabolic ratios in poor metabolizers. Safety evaluations, including electrocardiograms, indicated that the combination was well tolerated, with no difference between extensive and poor metabolizer phenotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 47
- 10.1038/clpt.1992.77 · DOI
- 10.2174/1389450013348335 · DOI · Paper page
- Liu Y, 2003, Dextromethorphan protects dopaminergic neurons against inflammation‐mediated degeneration through inhibition of microglial activation, J Pharmacol Exp Ther., 21, 21
- 10.1016/S0024-3205(02)02309-3 · DOI
- Desmeules JA, 1999, Contribution of cytochrome P‐4502D6 phenotype to the neuromodulatory effects of dextromethorphan, J Pharmacol Exp Ther., 288, 607, 10.1016/S0022-3565(24)37996-0 · DOI
- 10.1016/0028-3908(87)90275-9 · DOI · Paper page
- 10.1016/0006-8993(88)91497-7 · DOI
- 10.1016/0014-2999(93)90849-D · DOI
- 10.1111/j.1600-0404.1997.tb00231.x · DOI
- 10.1097/00002826-199619020-00009 · DOI
- 10.1097/00002826-198908000-00010 · DOI
- 10.1007/PL00007759 · DOI
- 10.1016/0304-3959(94)90056-6 · DOI · Paper page
- 10.1016/S0002-9343(99)00009-1 · DOI · Paper page
- 10.1007/BF03018952 · DOI
- 10.1097/00000542-200205000-00005 · DOI · Paper page
- 10.1016/S0304-3959(01)00455-9 · DOI
- 10.1097/00002508-200209000-00002 · DOI
- 10.1016/S0885-3924(99)00125-6 · DOI
- 10.1038/clpt.1985.235 · DOI · Paper page
- 10.1016/0006-8993(87)90070-9 · DOI · Paper page
- Duche J‐C, 1993, Dextromethorphan O‐demethylation and dextrorphan glucuronidation in a French population, Int J Clin Pharmacol Ther Toxicol., 31, 392
- 10.1023/A:1015925225766 · doi:10.1023/a:1015925225766
- 10.3171/jns.1996.84.5.0860 · DOI
- 10.1016/S0140-6736(84)92591-1 · DOI
- 10.1097/00007691-198804000-00021 · doi:10.1097/00007691-198804000-00021
- 10.1097/00008571-199808000-00006 · DOI
- 10.1111/j.1365-2125.1986.tb05251.x · DOI
- Smith R, 1995, The treatment of affective lability with dextromethorphan, Neurology, 54, 604P
- 10.1007/BF00558166 · doi:10.1007/bf00558166
- 10.1002/(SICI)1099-081X(1998110)19:8<541::AID-BDD138>3.0.CO;2-8 · doi:10.1002/(sici)1099-081x(1998110)19:8<541::aid-bdd138>3.0.co;2-8
- Rakhit A, 1982, Improved liquid‐chromatographic assay of quinidine and its metabolites in biological fluids, Clin Chem, 28, 1505, 10.1093/clinchem/28.7.1505 · doi:10.1093/clinchem/28.7.1505
- 10.1201/b14095 · DOI · Paper page
- 10.1056/NEJM199801013380107 · DOI
- 10.1111/j.1600-0404.1996.tb00181.x · DOI
- 10.1046/j.1365-2125.1999.00029.x · DOI
- 10.1016/S0009-9236(96)90056-9 · DOI
- 10.1097/00004714-199508000-00005 · DOI · Paper page
- 10.1002/ana.410360619 · DOI
- 10.1111/j.2042-7158.1998.tb06914.x · DOI
- 10.1002/1097-0142(19931215)72:12<3553::AID-CNCR2820721203>3.0.CO;2-B · DOI · Paper page
- 10.1016/S0024-3205(02)01799-X · doi:10.1016/s0024-3205(02)01799-x
- 10.1161/01.CIR.99.4.552 · DOI · Paper page
- 10.1016/S0022-3565(24)37075-2 · DOI · Paper page
- 10.1067/mcp.2000.109156 · DOI · Paper page
- 10.1097/00004714-199808000-00014 · DOI
- 10.1016/0002-8703(78)90200-4 · doi:10.1016/0002-8703(78)90200-4
Cited by
Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: A randomized trial
Brooks, B. R., Thisted, R. A., Appel, S. H., Bradley, W. G., Olney, R. K., Berg, J. E., Pope, L. E., & Smith, R. A. (2004) · Neurology · doi:10.1212/01.wnl.0000142042.50528.2f · Cited by 434
Self-citationAddressing phenoconversion: the Achilles' heel of personalized medicine
Shah, R. R., & Smith, R. L. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12441 · Cited by 278
Dezentjé, V. O., van Blijderveen, N. J. C., Gelderblom, H., Putter, H., van Herk-Sukel, M. P. P., Casparie, M. K., Egberts, A. C. G., Nortier, J. W. R., & Guchelaar, H.-J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0894 · Cited by 163
Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
Nguyen, L., Thomas, K. L., Lucke-Wold, B. P., Cavendish, J. Z., Crowe, M. S., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.016 · Cited by 141
Tabuteau, H., Jones, A., Anderson, A., Jacobson, M., & Iosifescu, D. V. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21080800 · Cited by 140
Metadata
- Authors
- Pope, L. E., Khalil, M. H., Berg, J. E., Stiles, M., Yakatan, G. J., & Sellers, E. M.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2004-10
- Volume
- 44
- Issue
- 10
- Pages
- 1132-1142
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2000782600
- Cited by
- 122
- References
- 0
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics of Dextromethorphan After Single or Multiple Dosing in Combination With Quinidine in Extensive and Poor Metabolizers. https://app.cochat.ai/papers/10.1177/0091270004269521
- The paper
- Pope, L. E., Khalil, M. H., Berg, J. E., Stiles, M., Yakatan, G. J., & Sellers, E. M. (2004). Pharmacokinetics of Dextromethorphan After Single or Multiple Dosing in Combination With Quinidine in Extensive and Poor Metabolizers. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270004269521
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.